Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MLTX Stock Forecast 2026-2027
$17.90
Current Price
$1.32B
Market Cap
Buy 11
Hold 2
Sell 2
Wall St Analyst Ratings
Distance to MLTX Price Targets
+157.0%
To High Target of $46.00
+67.6%
To Median Target of $30.00
-66.5%
To Low Target of $6.00
MLTX Price Momentum
-6.7%
1 Week Change
+1.1%
1 Month Change
-61.8%
1 Year Change
+35.8%
Year-to-Date Change
-71.5%
From 52W High of $62.75
+200.8%
From 52W Low of $5.95
📊 TOP ANALYST CALLS
Did MLTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MoonLake is one of their latest high-conviction picks.
Latest MLTX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, MLTX has a bullish consensus with a median price target of $30.00 (ranging from $6.00 to $46.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $17.90, the median forecast implies a 67.6% upside. This outlook is supported by 11 Buy, 2 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLTX Analyst Ratings
11
Buy
2
Hold
2
Sell
MLTX Price Target Range
Low
$6.00
Average
$30.00
High
$46.00
Current: $17.90
Latest MLTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2026 | Needham | Serge Belanger | Buy | Maintains | $30.00 |
| May 11, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $45.00 |
| Mar 30, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 23, 2026 | Wolfe Research | Outperform | Upgrade | $N/A | |
| Mar 19, 2026 | Rothschild & Co | Buy | Upgrade | $N/A | |
| Mar 11, 2026 | Clear Street | Buy | Maintains | $N/A | |
| Mar 2, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 26, 2026 | Needham | Buy | Reiterates | $N/A | |
| Feb 24, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Feb 23, 2026 | BTIG | Buy | Maintains | $N/A | |
| Feb 23, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 20, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 9, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 15, 2026 | Goldman Sachs | Sell | Downgrade | $N/A | |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 9, 2026 | BTIG | Buy | Upgrade | $N/A | |
| Nov 21, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 3, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A |
MoonLake Immunotherapeutics (MLTX) Competitors
The following stocks are similar to MoonLake based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MoonLake Immunotherapeutics (MLTX) Financial Data
MoonLake Immunotherapeutics has a market capitalization of $1.32B with a P/E ratio of -5.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -77.8%.
Valuation Metrics
Market Cap
$1.32B
Enterprise Value
$1.09B
P/E Ratio
-5.1x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.2%
Current Ratio
8.6x
Debt/Equity
39.7x
ROE
-77.8%
ROA
-36.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MoonLake Immunotherapeutics (MLTX) Business Model
About MoonLake Immunotherapeutics
What They Do
Develops therapies for inflammatory diseases.
Business Model
The company operates as a clinical-stage biopharmaceutical entity, focusing on innovative therapies targeting IL-17A and IL-17F to treat serious inflammatory diseases. It generates revenue through the development and commercialization of its lead candidate, Sonelokimab, alongside other potential therapies by engaging in global research and clinical programs.
Additional Information
MoonLake Immunotherapeutics addresses significant unmet medical needs in conditions such as psoriasis and psoriatic arthritis, aiming to improve patients' quality of life. Founded by Jorge Santos da Silva, the company is positioned as a leader in advancing biopharmaceutical solutions for dermatological and rheumatological disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
130
CEO
Dr. Jorge Santos da Silva Ph.D.
Country
Switzerland
IPO Year
2020
Website
www.moonlaketx.comMoonLake Immunotherapeutics (MLTX) Latest News & Analysis
Latest News
Quick Summary
MoonLake Immunotherapeutics shares rose after the company announced a meeting with the FDA in April.
Why It Matters
The FDA meeting suggests potential progress for MoonLake's drug development, increasing investor confidence and likely boosting share prices as regulatory clarity improves.
Source: Investors Business Daily
Market Sentiment:
Negative
Quick Summary
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported a positive outcome from its final pre-BLA meeting with the FDA regarding its Nanobody® SLK for inflammatory diseases.
Why It Matters
Positive FDA meeting outcomes can accelerate product approvals, potentially boosting MoonLake's stock price and attracting investor interest in its innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares rose after positive results from its final pre-BLA FDA meeting for sonelokimab (SLK) in treating hidradenitis suppurativa (HS).
Why It Matters
Positive FDA meeting outcomes for MoonLake's sonelokimab boost share prices, indicating potential approval and market entry, which could enhance revenue and investor confidence.
Source: Benzinga
Market Sentiment:
Positive
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
1 month ago
Quick Summary
CEO Jorge Santos da Silva sold 150,000 shares for about $2.75 million at an average price of $18.35 per share, representing 4.9% of his holdings.
Why It Matters
CEO Jorge Santos da Silva's sale of 150,000 shares may signal insider sentiment, potentially affecting stock price and investor confidence in the company’s future performance.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
BVF sold 3.75 million shares for about $62.96 million on April 2, 2026, reducing its direct holdings by 78.3% to 1,039,238 shares.
Why It Matters
BVF's significant share sale indicates a potential loss of confidence in the company's future, which could negatively impact stock prices and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
MoonLake Immunotherapeutics announced long-term results from its Phase 3 VELA-1 and VELA-2 trials for moderate-to-severe HS. Data will be presented at the 2026 AAD Annual Meeting.
Why It Matters
Positive results from Phase 3 trials for MoonLake's therapies could enhance market confidence, potentially driving stock value and interest from institutional investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MLTX Stock
What is MoonLake Immunotherapeutics's (MLTX) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, MoonLake Immunotherapeutics (MLTX) has a median price target of $30.00. The highest price target is $46.00 and the lowest is $6.00.
Is MLTX stock a good investment in 2026?
According to current analyst ratings, MLTX has 11 Buy ratings, 2 Hold ratings, and 2 Sell ratings. The stock is currently trading at $17.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MLTX stock?
Wall Street analysts predict MLTX stock could reach $30.00 in the next 12 months. This represents a 67.6% increase from the current price of $17.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MoonLake Immunotherapeutics's business model?
The company operates as a clinical-stage biopharmaceutical entity, focusing on innovative therapies targeting IL-17A and IL-17F to treat serious inflammatory diseases. It generates revenue through the development and commercialization of its lead candidate, Sonelokimab, alongside other potential therapies by engaging in global research and clinical programs.
What is the highest forecasted price for MLTX MoonLake Immunotherapeutics?
The highest price target for MLTX is $46.00 from at , which represents a 157.0% increase from the current price of $17.90.
What is the lowest forecasted price for MLTX MoonLake Immunotherapeutics?
The lowest price target for MLTX is $6.00 from at , which represents a -66.5% decrease from the current price of $17.90.
What is the overall MLTX consensus from analysts for MoonLake Immunotherapeutics?
The overall analyst consensus for MLTX is bullish. Out of 4 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 2 as Sell, with a median price target of $30.00.
How accurate are MLTX stock price projections?
Stock price projections, including those for MoonLake Immunotherapeutics, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 8:19 AM UTC